- Home
- REE vs PULM Comparison
REE vs PULM Comparison
Compare REE & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- PULM
- Stock Information
- Founded
- REE 2011
- PULM 2003
- Country
- REE Israel
- PULM United States
- Employees
- REE N/A
- PULM N/A
- Industry
- REE Auto Manufacturing
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- PULM Health Care
- Exchange
- REE Nasdaq
- PULM Nasdaq
- Market Cap
- REE 22.4M
- PULM 18.3M
- IPO Year
- REE N/A
- PULM N/A
- Fundamental
- Price
- REE $0.74
- PULM $4.84
- Analyst Decision
- REE Strong Buy
- PULM
- Analyst Count
- REE 2
- PULM 0
- Target Price
- REE $11.75
- PULM N/A
- AVG Volume (30 Days)
- REE 129.4K
- PULM 4.3K
- Earning Date
- REE 12-16-2025
- PULM 10-16-2025
- Dividend Yield
- REE N/A
- PULM N/A
- EPS Growth
- REE N/A
- PULM N/A
- EPS
- REE N/A
- PULM N/A
- Revenue
- REE $183,000.00
- PULM $3,000.00
- Revenue This Year
- REE $327.73
- PULM N/A
- Revenue Next Year
- REE $36,888.82
- PULM $134.88
- P/E Ratio
- REE N/A
- PULM N/A
- Revenue Growth
- REE N/A
- PULM N/A
- 52 Week Low
- REE $0.53
- PULM $4.26
- 52 Week High
- REE $11.72
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- REE 37.61
- PULM 47.70
- Support Level
- REE $0.66
- PULM $4.26
- Resistance Level
- REE $0.99
- PULM $4.85
- Average True Range (ATR)
- REE 0.11
- PULM 0.24
- MACD
- REE -0.02
- PULM -0.02
- Stochastic Oscillator
- REE 22.23
- PULM 61.11
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).